Laffleur F
Key Features Dual-mechanism design: GHRH-receptor agonism (CJC-1295) + GHSR agonism (Ipamorelin) for complementary GH-axis interrogation 99% Purity (HPLC/MS verified): Consistent material for reproducible protocols Protocol-friendly kinetics: Short, high-amplitude GH pulse (Ipamorelin) alongside prolonged GH/IGF-1 support (CJC-1295) in model systems GMP-compliant manufacturing (USA): Batch-to-batch reliability COA included: Full lot documentation Specifications Identity: CJC-1295 /Ipamorelin USA cGMP Produced Form & Sizes: 10 mg vials Appearance: White to off-white lyophilized powder Purity: 99% (HPLC/MS verified) Manufacturing: GMP-compliant facility, USA Storage: 20 C, desiccated
( f ) Circulating BHB in OXCT1 iKO mice on CD and KD
Ingredients: Water/Aqua/Eau, Octyldodecyl Neopentanoate, Cetearyl Alcohol, Sodium Polystyrene Sulfonate, Glycerin, Caprylic/Capric Triglyceride, Dimethicone, Behenyl Alcohol, Hydrogenated Vegetable Glycerides, Trifluoromethyl C1-4 Alkyl Dimethicone, Glyceryl Stearate, PEG-100 Stearate, Butyrospermum Parkii (Shea) Butter, S-Palmitoylglutathione, Steareth-20, Macadamia Ternifolia Seed Oil, Salvia Hispanica Seed Oil, Xanthan Gum, Linum Usitatissimum (Linseed) Seed Oil, Ethylhexylglycerin, Lactic Acid, Helianthus Annuus (Sunflower) Seed Oil, Rosmarinus Officinalis (Rosemary) Leaf Extract, Disodium EDTA, Sodium Hydroxide, Butylene Glycol, Fucus Vesiculosus Extract, Cryptomeria Japonica Leaf Extract, Hexylene Glycol, Caprylyl Glycol, Phenoxyethanol, Silica, Titanium Dioxide (CI 77891), Iron Oxides (CI 77499)
